Therefore, targeting CD39 with therapeutic antibodies to enhance eATP signaling over that of adenosinergic effects is a promising approach for cancer treatment, with theoretical advantages over just targeting CD73 or adenosinergic A2A receptors (32). Here, ENTPD1 is linked to cancer.